ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
The complement system, a key component of innate immunity, exerts profound influence on the initiation, progression and destabilisation of atherosclerotic plaques. Activation may proceed via the ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results